B3 Labs has confirmed it has had 525 certified products included on the Food Standards Agency’s (FSA) list of CBD products linked to credible applications.
Any company wishing to sell CBD products in the UK is required to make a Novel Foods application to the FSA. The organisation recently published the public list of applications, with final authorisations expected by 2023.
The list, which is now closed for further applications, currently contains almost 12,000 products.
B3 Labs has described its products’ inclusion on the list as a landmark moment for the company.
Read more: Novel Foods applicant responds to EFSA’s decision to pause evaluations
CEO at B3 Labs, Marc Burbidge, commented: “This is a landmark moment for B3 Labs, but also Europe’s cannabis market as a whole.
“At B3 we are committed to ensuring consumers know what they are getting when purchasing CBD products, and today’s news is a major step in our growth journey.
“We hope to see more of the consumer cannabis market following suit to drive transparency and assurance across the industry.”
B3 Labs was Europe’s first BRCGS (Brand Reputation Compliance Global Standards) certified CBD manufacturer, obtaining AA grade certification in 2021.
Read more: EFSA puts CBD Novel Foods evaluations on hold due to lack of data
The company has stated that combining the highest level of food certification and cannabinoid knowledge has allowed B3 to set a clear benchmark to the rest of the cannabis industry, as it drives legitimacy within the sector and ensures it matches up to standards in the traditional foods market.
Analysis published by Leafreport last year revealed a lack of transparency and third-party testing in the consumer cannabis market, finding that the majority of CBD consumer goods are not labelled with accurate information about their purity and potency.
By achieving the first step to novel foods authorisation, B3 Labs is driving change in the market, providing consumers with greater assurance over the safety, transparency and quality of its CBD products.
B3 Labs produces a range of CBD oils, gummies and vapes and was recently acquired by Sana Life Science, a leading specialist cannabis distributor based in the UK and operating in a number of markets across Europe, including the UK and Germany.
[activecampaign form=31]
